You are currently viewing Canada approves Pfizer-BioNTech Covid-19 vaccine

Canada approves Pfizer-BioNTech Covid-19 vaccine

OTTAWA: Canada on Wednesday approved the Pfizer-BioNTech Covid-19 vaccine, days after Britain became the first country to green-light and roll it out.
“Today, Canada reached a critical milestone in its fight against Covid-19 with the authorization of the first Covid-19 vaccine,” Health Canada said in a statement.
The vaccine, it said, had undergone a fast-tracked review while it was still in clinical trials, which concluded that it met “stringent safety, efficacy and quality requirements for use in Canada.”
Prime Minister Justin Trudeau said on Monday that as many as 249,000 doses would be received in December, with the first shipments to 14 sites across Canada arriving as early as next week and people receiving shots a day or two later.
Health care workers and vulnerable populations including the elderly are to be the first to receive it.
By September 2021, Trudeau said, most Canadians should be inoculated.
Thousands of Britons became the first in the Western world to receive the vaccine on Tuesday at the start of the biggest global vaccination drive in more than half a century.
The vaccine — which proved to be 95 percent effective in late-stage clinical trials — is administered in two doses, 21 days apart.
British health officials, however, warned on Wednesday that anyone with a history of significant allergic reactions should not get it right away, after two people suffered allergic reactions and needed treatment.
US giant Pfizer and its German partner BioNTech called Canada’s interim order for its emergency use “a historic moment in our collective fight against the Covid-19 pandemic” and “a major step towards returning to normalcy in Canada.”
They will continue providing data on its use for ongoing evaluation, according to Canada’s health department.
The federal government, meanwhile, has concluded pre-orders with several pharmaceutical companies — including AstraZeneca, Pfizer and BioNTech, Sanofi and GSK, Novavax, Johnson & Johnson, Medicago and Moderna — for 400 million doses, to ensure it eventually gets what it needs for its population of 38 million.app

Newspakistan.tv | YouTube Channel

M M Alam

M. M. Alam is a Pakistan-based working journalist since 1981. Karachi University faculty gold medalist Alam began his career four decades ago by writing for Dawn, Pakistan’s highest circulating English daily. He has worked for region’s leading publications, global aviation periodicals including Rotors (of USA) and vetted New York Times as permanent employee of daily Express Tribune. Alam regularly covers international aviation and defense-related events including Salon Du Bourget (France), Farnborough (United Kingdom), Dubai (UAE). Alam has reported thousands of events and interviewed hundreds of people in Pakistan, UAE, EU, UK and USA. Being Francophone Alam also coordinates with a number of French publications.